DOT Desk: NIPRO JMI Pharma Limited, the first Japan-Bangladesh joint venture pharma company,organized a scientific seminar on ‘Novel glucose lowering medication –Empagliflozin, a ground breaking innovation for Type 2 Diabetes’ at Inter Continental Hotel in the capital yesterday, reports The Daily Observer.
Professor Dr SM Ashrafuzzaman and Professor Emeritus Dr Hajera Mahtab attended the seminar as co-chairperson and chief guest respectively, according to a press release.
NIPRO JMI Pharma Chief Executive Officer (CEO) Md Mizanur Rahman presided over the seminar, while noted Endocrinologists Professor Dr Zafar Ahamed Latif and Professor Dr Md Faruque Pathan were also present on the occasion.
CEO Mizanur Rahman acclaimed marketing professional and said the seminar Nipro JMI Pharma has been working for healthcare services through providing best quality medicines as per guidance of NIPRO Corporation in Japan.
He expressed his sincere gratitude and thanks to the doctors for their kind support to expedite such holistic endeavour for mankind.
Endocrinologist and Assistant Professor Dr Tanjina Hossain as speaker presented that the use of novel Empagliflozin (Empa) for type-2 diabetes also reduces the risk of Cardiovasculardeath by 38 per cent.
The American Diabetes Association (ADA)-2019 guidelines recommended the benefits of Empagliflozin for Type 2 Diabetic patients who have Cardiovascular Disease, Heart Failure, Kidney Disease and Obesity.
Our time is a news portal